Blueprint Medicines Corporation
Blueprint Medicines Corporation (BPMC) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Blueprint Medicines Corporation (BPMC), covering cash flow, earnings, and balance sheets.
Blueprint Medicines Corporation (BPMC) Income Statement & Financial Overview
Explore comprehensive income reports for Blueprint Medicines Corporation BPMC, broken down by year and quarter.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $149.41M | $146.37M | $128.18M | $138.16M |
| Cost of Revenue | $2.80M | $7.45M | $1.93M | $11.21M |
| Gross Profit | $146.61M | $138.92M | $126.25M | $126.95M |
| Gross Profit Ratio | $0.98 | $0.95 | $0.98 | $0.92 |
| R&D Expenses | $91.89M | $83.67M | $85.30M | $80.65M |
| SG&A Expenses | $95.81M | $96.45M | $89.93M | $89.34M |
| Operating Expenses | $187.70M | $180.12M | $175.23M | $169.99M |
| Total Costs & Expenses | $190.50M | $187.57M | $177.16M | $181.20M |
| Interest Income | $0.00 | $10.39M | $11.15M | $9.94M |
| Interest Expense | -$8.13M | $18.17M | $18.77M | $16.80M |
| Depreciation & Amortization | -$34.24M | $4.001M | $3.86M | $3.62M |
| EBITDA | -$41.09M | -$27.11M | -$33.37M | -$29.48M |
| EBITDA Ratio | -$0.27 | -$0.19 | -$0.26 | -$0.21 |
| Operating Income | -$41.09M | -$41.20M | -$48.97M | -$43.05M |
| Operating Income Ratio | -$0.27 | -$0.28 | -$0.38 | -$0.31 |
| Other Income/Expenses (Net) | $42.37M | -$8.08M | -$7.03M | -$6.85M |
| Income Before Tax | $1.28M | -$49.28M | -$56.003M | -$49.89M |
| Income Before Tax Ratio | $0.009 | -$0.34 | -$0.44 | -$0.36 |
| Income Tax Expense | $789000.00 | $672000.00 | $273000.00 | $102000.00 |
| Net Income | $496000.00 | -$49.96M | -$56.28M | -$49.99M |
| Net Income Ratio | $0.003 | -$0.34 | -$0.44 | -$0.36 |
| EPS | $0.01 | -$0.79 | -$0.89 | -$0.80 |
| Diluted EPS | $0.01 | -$0.79 | -$0.89 | -$0.80 |
| Weighted Avg Shares Outstanding | $63.60M | $63.60M | $63.38M | $62.85M |
| Weighted Avg Shares Outstanding (Diluted) | $63.60M | $63.60M | $63.38M | $62.85M |
The company's financials show resilient growth, with revenue advancing from $138.16M in Q2 2024 to $149.41M in Q1 2025. Gross profit remained healthy with margins at 98% in Q1 2025 compared to 92% in Q2 2024. Operating income hit -$41.09M last quarter, sustaining a consistent -27% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$41.09M. Net income rose to $496000.00, while earnings per share reached $0.01. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan